Canopy Growth completes previously announced acquisition of Beckley Canopy Therapeutics

SMITHS FALLS, ON & LONDON, Oct. 15, 2019 /CNW/ - Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) ("Canopy Growth" or the "Company") has closed the previously announced acquisition of all outstanding shares in the global cannabinoid based research company Beckley Canopy Therapeutics (Beckley Canopy), including the joint commercial venture Spectrum Biomedical UK. These teams will now be integrated into the broader Spectrum Therapeutics organization to increase the breadth of the clinical research being pursued under the Spectrum banner and to combine continental European and United Kingdom commercial teams.

As a part of the acquisition, Canopy Growth's European management structure will evolve. Paul Steckler and Steven Wooding will assume the roles of Co-Managing Directors in charge of all European operations. Paul is a seasoned pharmaceutical executive with over 20 years' experience in commercial roles, having worked in both large and small pharmaceutical companies including Pfizer. Steve has held multiple positions within a 27-year career at Janssen, the Pharmaceutical arm of Johnson & Johnson. Most recently, he was head of Global Commercial Strategy and Market Access for Janssen.

"The acquisition comes at a time when commercial opportunities across Europe are ramping up," said Mark Zekulin, CEO, Canopy Growth. "Spectrum Biomedical has completed all necessary approvals to import cannabis into the UK market and is proud to facilitate patient access to safe cannabinoid-based medicines there. Consolidating our UK-based operations will allow Canopy to simultaneously improve its research and commercial capabilities across the continent."

Beckley Canopy was formed as a joint venture in January 2018 between Beckley Research & Innovations ("BRI") and Canopy Growth to research and develop clinically validated cannabis-based medicines, with a strong focus on intellectual property protection. The research platform combined European and North American-based leaders in cannabis research from BRI and Canopy Growth to create a strong and complementary UK-based European partnership. Since its inception, Beckley Canopy has made significant progress in its core research areas, added additional indications of interest, and worked closely and in a complementary fashion with the global Canopy research team.

Here's to Future (European) Growth.

About Canopy Growth Corporation
Canopy Growth (TSX:WEED, NYSE:CGC) is a world-leading diversified cannabis, hemp and cannabis device company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms, as well as medical devices through Canopy Growth's subsidiary, Storz & Bickel GMbH & Co. KG. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time. Canopy Growth has operations in over a dozen countries across five continents.

Canopy Growth's medical division, Spectrum Therapeutics is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public's understanding of cannabis, and has devoted millions of dollars toward cutting edge, commercializable research and IP development. Spectrum Therapeutics sells a range of full-spectrum products using its colour-coded classification Spectrum system as well as single cannabinoid Dronabinol under the brand Bionorica Ethics.

Canopy Growth operates retail stores across Canada under its award-winning Tweed and Tokyo Smoke banners. Tweed is a globally recognized cannabis brand which has built a large and loyal following by focusing on quality products and meaningful customer relationships.

From our historic public listing on the Toronto Stock Exchange and New York Stock Exchange to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth. Canopy Growth has established partnerships with leading sector names including cannabis icons Snoop Dogg and Seth Rogen, breeding legends DNA Genetics and Green House Seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates eleven licensed cannabis production sites with over 4.7 million square feet of production capacity, including over one million square feet of GMP certified production space. For more information visit www.canopygrowth.com

Notice Regarding Forward Looking Statements
This news release contains "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements include statements with respect to strategic acquisitions. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including the Company's ability to satisfy provincial sales contracts or provinces purchasing all cannabis allocated to them, and such risks contained in the Company's annual information form dated June 25, 2019 and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

SOURCE Canopy Growth Corporation

Canopy Growth Announces Sale of Stake in AusCann

The companies will continue to collaborate in the Australian market

SMITHS FALLS, ON, Oct. 15, 2019 /CNW/ - Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) ("Canopy Growth") has sold its 42,087,639 shares in Australian cannabis company AusCann Group Holdings (AusCann) via an off market block trade at $0.15 per share for gross proceeds of $6.3 million. The trade was facilitated by Canaccord Australia.

The sale represents Canopy Growth's total 13.2% interest in AusCann.

"Canopy Growth remains optimistic about the future of the Australian medical cannabis market and will continue to collaborate with the team at Auscann to support greater physician understanding and patient access to high quality cannabis products throughout Australia," said Mark Zekulin, CEO, Canopy Growth. "The decision to divest our position in AusCann, which we obtained three years ago in exchange for support provided, will allow us to sharpen our focus on our wholly-owned operations in the market, while continuing to collaborate with our partners at AusCann."

Dr. Marcel Bonn-Miller, Canopy Growth's Global Senior Director of Clinical Science, will continue to sit on the AusCann Board of Directors to facilitate future collaboration.

Here's to Future Growth.

Notice Regarding Forward Looking Statements
This news release contains "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements include statements with respect to divesting shares. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including the Company's ability to satisfy provincial sales contracts or provinces purchasing all cannabis allocated to them, and such risks contained in the Company's annual information form dated June 25, 2019 and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

SOURCE Canopy Growth Corporation

Avicanna Commences Trading on the OTCQX Market in the United States

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/

TORONTO, Oct. 15, 2019 /CNW/ - Avicanna Inc. ("Avicanna" or the "Company") (TSX: AVCN) (OTCQX: AVCNF), a biopharmaceutical company focused on the development, manufacturing and commercialization of cannabinoid-based products, is pleased to announce that its common shares will commence trading today on the OTCQX® Best Market in the United States under the symbol "AVCNF".

The OTCQX Best Market provides added service, value and convenience to U.S. investors, brokers and institutions seeking to trade Avicanna shares. OTCQX is OTC Markets Group's premier market for established, investor-focused U.S. and international companies. To be eligible, companies must meet high financial standards, follow best practice corporate governance, demonstrate compliance with U.S. securities laws, be current in their disclosure, and have a professional third-party sponsor introduction.

"Trading on the OTCQX Market represents a significant step in Avicanna's capital markets strategy and journey to become an international leader in the biopharmaceutical industry. The achievement will allow us increased access to the U.S. capital markets and industry participants with extensive experience in evaluating pharmaceutical companies. Trading on OTCQX is also expected to provide a streamlined process for U.S. investors to transact in our securities and enhanced liquidity for all shareholders," stated Setu Purohit, President of Avicanna Inc.

About Avicanna

Avicanna is an Ontario corporation focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products through its two main business segments, cultivation and research and development.

Avicanna's two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia are the base for Avicanna's cultivation activities. These two companies are licensed to cultivate and process cannabis for the production of cannabis extracts and purified cannabinoids including cannabidiol (CBD) and tetrahydrocannabinol (THC).

Avicanna's research and development business is primarily conducted out of Canada at its headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto. Avicanna's scientific team develops products, and Avicanna has also engaged the services of researchers at the Leslie Dan Faculty of Pharmacy at the University of Toronto for the purpose of optimizing and improving upon its products.

Avicanna's research and development and cultivation activities are focused on the development of its key products, including plant-derived cannabinoid pharmaceuticals, phyto-therapeutics, derma-cosmetics and Extracts (defined as plant-derived cannabinoid extracts and purified cannabinoids, including distillates and isolates), with a goal of eventually having these products manufactured and distributed through various markets.

Stay Connected

For more information about Avicanna, visit www.avicanna.com, call 1-647-243-5283, or contact Setu Purohit, President by email info@avicanna.com.

Cautionary Note Regarding Forward-Looking Information and Statements

Certain information in this press release contains forward-looking statements. Such statements include but are not limited to the expected benefits from the commencement of trading on the OTCQX Market. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict, including the risk factors set out under the heading "Risk Factors" in the Company's long form final prospectus dated July 8, 2019. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements, unless and until required by securities laws applicable to the Company.

SOURCE Avicanna Inc.

Health Canada Leverages Strainprint^RTechnologies’ Real-Time Observational Data and Analytics to Better Understand Cannabis Use in Canada

Strainprint Analytics Research Platform to Help Support Canadian Government
Policies Post-Cannabis LegalizationF

TORONTO (Oct. 15 2019) – Strainprint^RTechnologies Ltd. (Strainprint), the leader in cannabis data and analytics is proud to announce that Health Canada has subscribed to use Strainprint Analytics to further research Canadians’ use of cannabis in the post-legalization era.

Health Canada views the legalization and regulation of all cannabis through a lens of public safety and is regarded as one of the most respected regulatory bodies in the world. Raising awareness about the health effects of cannabis through research and public education is fundamental to Health Canada’s mandate, which Strainprint’s real-world observational data is uniquely positioned to support.

Health Canada now has access to over 1.4 million anonymized patient reported outcomes (70+ million data points on real-time patient use and strain efficacy) through Strainprint Analytics, the most sophisticated cannabis research platform available today. Strainprint Analytics is the self-serve web-companion to published reports (like the Candian Medical Cannabis Experience: A 2019 Patient Retrospective) and custom research that Strainprint’s research team conducts on its data for industry.

Various departments at Health Canada will use Strainprint Analytics to:

Understand how optimal products and administration methods vary by gender and age across the country;
See how products and producers rank against each other for consistency and efficacy;
Get better and faster visibility into any adverse reactions; and
Track how Candian patient use has changed pre and post legalization.

“Canada has developed the most sophisticated and compliant medical cannabis program in the world, which makes Health Canada, arguably, one of the most important data customers in the industry,” said Strainprint CEO, Andrew Muroff. “We are incredibly proud that they have chosen to work with us as a trusted authority on patient data.”

For more information visit www.strainprintanalytics.com.

About Strainprint^R

Founded in Toronto in 2016, Strainprint^RTechnologies Ltd. is the leading demand-side cannabis data and analytics company. With the world's largest longitudinal, observational dataset of its kind and a mission to advance the scientific understanding of cannabis and its legitimization as a mainstream therapy, Strainprint helps medical cannabis patients and doctors to use cannabis in the most effective and responsible way possible. Strainprint's comprehensive research platform provides advanced business intelligence and treatment guidance to producers, retailers, medical practitioners, pharmacies, government and industry. Strainprint is HIPAA, PIPEDA and PHIPA privacy compliant, military-grade encrypted, and all patient data is completely anonymized and at rest in Canada. Strainprint can be seamlessly embedded or integrated with most electronic medical records (EMR) and seed2sale software systems. Strainprint Analytics is accessed by customer subscription. The Strainprint App is free to patients and can be downloaded from both the iOS App Store and Google Play Store. www.strainprint.ca, facebook, twitter, linkedin. Strainprint Reports are available at https://strainprint.ca/strainprint-reports/.

Vaping is not a safe substitute for smoking and can damage the lungs—a case study of granulomatosis resulting from vaping

NEW ORLEANS (Oct. 14, 2019) Vaping is not a low-risk substitute for smoking cigarettes, according to researcher Charlie Lin, MD, who authored a case study of a 34-year-old former smoker diagnosed with granulomatosis attributed to two months of electronic cigarette use. Dr. Lin will present his case study at the CHEST Annual Meeting 2019 in New Orleans.

“This case of granulomatosis secondary to electronic cigarette use exemplifies an unintended consequence of ‘vaping,’” Dr. Lin wrote. Granulomas destroy healthy tissue and inflame blood vessels, which can limit blood flow to organs including the lungs.

Electronic cigarettes vaporize liquids for inhalation to simulate the combustion of smoking traditional cigarettes. Until recently, e-cigarettes, with their lack of combustion-produced toxins, were thought to be lower risk than traditional cigarettes. Consequently, e-cigarettes have been heralded as having a perceived role in smoking cessation.

The subject of the case study sought medical evaluation for a new cough and wheeze 10 months after undergoing a bilobectomy for lung cancer. The patient acknowledged that she had begun vaping two months earlier. After a variety of tests, she was diagnosed with granulomatosis.

“Given the recent introduction of electronic cigarettes into our culture and the relatively limited availability of studies delineating health risks arising from their use, further research is necessary to quantify and characterize exposures of specific chemicals within vaporized liquids,” continued Dr. Lin. “This can assist with determination of toxic doses and may inform future regulations regarding safe levels of constituent components within commercially available liquids. Importantly, such investigation can help bolster public knowledge and continue to objectively demonstrate that “vaping,” or inhalation of aerosolized liquids, is not benign, and in fact has known pulmonary consequences,” Dr. Lin concluded.

Victor Test, MD, Co-Chair of the CHEST Scientific Program Committee and Professor of Texas Tech University Health Sciences Center, commented: “This case report is reflective of the recent increase in reported vaping-associated lung injury. It brings to the surface how little we understand about vaping and its effects on lung health though it does suggest that vaping is not a benign habit.”

ABOUT CHEST 2019

CHEST 2019 is the 85th annual meeting for the American College of Chest Physicians held Oct. 19 to Oct. 23, 2019, in New Orleans. The American College of Chest Physicians, publisher of the journal CHEST®, is the global leader in advancing best patient outcomes through innovative chest medicine education, clinical research and team-based care. Its mission is to champion the prevention, diagnosis and treatment of chest diseases through education, communication and research. It serves as an essential connection to clinical knowledge and resources for its 19,000 members from around the world who provide patient care in pulmonary, critical care and sleep medicine. For more information about CHEST 2019, visit chestmeeting.chestnet.org, or follow CHEST meeting hashtag, #CHEST2019, on social media.

Smokers have more blood clots in the lung, leading to higher hospital readmission rates

NEW ORLEANS (Oct. 14, 2019) Patients with lung blood clots who smoke are more likely to be readmitted for lung blood clots than nonsmokers, according to Kam Sing Ho, MD, from Mount Sinai St. Luke’s and Mount Sinai West in New York City, who will present the study findings at the CHEST Annual Meeting 2019 in New Orleans.

Pulmonary emboli (PE), or blood clots in the lung, are common and are associated with 100,000 deaths annually. Risk factors include advanced age, surgery, trauma, prolonged immobility, cancer, pregnancy, estrogen therapy, congestive heart failure and defects in blood coagulation factors.

The researchers conducted a retrospective study using the AHRQ-HCUP Nationwide Readmission Database to study the role of smoking in hospital readmissions with a primary diagnosis of pulmonary embolism and a secondary diagnosis of tobacco dependence, also called active smoking.

“Active smokers have a higher hospital readmission rate (34.2%) for pulmonary embolism,” stated Dr. Ho. “We found that 11% of smokers and nearly 9% of nonsmokers with PE were readmitted to the hospital within 30 days. The most common cause (13%) for readmission was PE. Smoking was an independent predictor associated with higher readmission rate.”

The investigators found that readmitted patients were twice as likely to die than patients on their first admission (6.27 % vs. 3.16%). Smoking was associated with readmission as were female gender, atrial fibrillation, in-hospital oxygen requirement, Medicare insurance and additional illnesses. Private insurance and higher income status were associated with fewer readmissions.

“Previous reports have shown that smoking cessation services are underutilized within the hospital,” commented Dr. Ho. “The National Readmission Database provides a platform to identify these correlations. This is an early study with promising results, which we are planning further refine with our own hospital database. In the future, we want to incorporate smoking cessation services for all adults hospitalized with pulmonary emboli.”

Michelle Cao, MD, member of the American College of Chest Physicians Scientific Presentations and Awards Committee and Clinical Associate Professor at Stanford University, California, addressed the importance of smoking cessation and the next step in implementation: “This study provides an opportunity to evaluate methods of implementing tobacco cessation, in light of possible increased risk of pulmonary embolism in smokers. One of the questions posed is how can we better utilize in- hospital smoking cessation programs as well as outpatient programs. Can this service be driven by primary care providers and/or pulmonologists? Successful smoking cessation programs would have major implications on morbidity, mortality as well as economic burden.”

ABOUT CHEST 2019

Almost One-Third of Canadians Say Back Pain Limiting Their Work & Daily Lives

Canadians urged to #GetSpineActive on World Spine Day to prevent injuries and physical
disorders; one in four work absences due to back pain, second only to common cold

TORONTO, Oct. 16, 2019 /CNW/ - According to the Canadian Chiropractic Association (CCA), more than 11 million Canadians suffer from an injury or disorder that affects their movement, with one in eight reporting a chronic back problem and almost one-third indicating activity limitations due to back pain.

These numbers are higher than they need to be, according to chiropractors across the country who treat approximately 4.5 million Canadians each year. They also shed light on the broad societal and economic impact of those affected, including that forty per cent of all work absences are due to back pain, second only to the common cold.

Coinciding with World Spine Day on October 16, the CCA is raising awareness of the treatment options available to Canadians, and the importance of physical activity, with a campaign called "Get Spine Active" (#GetSpineActive). World Spine Day has become a focus in raising awareness of back pain and other spinal issues. With health professionals, exercise and rehabilitation experts, public health advocates, schoolchildren and patients all taking part, World Spine Day will be celebrated on every continent.

"Canadians who want to improve their physical health and well-being can do so by staying active," said Alison Dantas, Chief Executive Officer at Canadian Chiropractic Association. "Now more than ever, we want to encourage Canadians to consider chiropractors as an integral member of their healthcare team to achieve better outcomes and improve their quality of life."

Chiropractors help Canadians reduce pain, restore function and improve quality of life
The spine is a critical part of the body, holding up the head, arms and torso. With over 60 joints in the spine, it's important that they function properly so the spine can keep the body upright while protecting spinal cord and nerves.

Chiropractors are spine, muscle, and nervous system experts who reduce pain and restore function, helping Canadians better manage their musculoskeletal pain. They are musculoskeletal (MSK) experts, providing the assessment, diagnosis, treatment and preventative care originating from the muscular, skeletal and nervous systems. Chiropractic is also a drug-free, non-invasive treatment.

According to the 2017 report All Pain, No Gain: Shining a Light on Canada's Back Pain and Opioid Crisis, 90 per cent of Canadians who have used a chiropractor to help with their muscle and joint pain believe that it improved their overall quality of life, more than any other method. And despite the high levels of satisfaction among those choosing a chiropractor for care, people in under-serviced parts of Canada often have no access to care for spinal pain and disability.

Injuries and physical disorders can become chronic and painful if left untreated
The number of Canadians affected by injuries, back pain and physical disorders is so significant that the CCA hopes to spark a robust dialogue among Canadians on World Spine Day around the seriousness of the issue, its impact, and simple ways to prevent and treat it. The most common injuries or disorders treated by chiropractors are sprains, strains, low back pain and neck pain. While conditions can be either mild or severe, they can become chronic if left undiagnosed and untreated.

"Too many Canadians leave their injuries and physical disorders untreated until they are in significant pain which limits mobility and their quality of life," said Dr. Sasha Hamid, an associate chiropractor with the CURAVITA Health Group in Ottawa. "In this case, movement truly is medicine and even simple exercises can help Canadians maintain flexibility and avoid chronic pain. It's time for more Canadians to take control of their physical health and well-being by looking after their spines and staying active."

Easy ways to #GetSpineActive
The CCA and Canada's chiropractors have several recommendations to help Canadians #GetSpineActive:

Start Moving: Being physically active helps prevent and manage injuries or disorders related to sprains, strains, low back pain and neck pain. It can also help maintain strength and mobility. Physical activity is also crucial to maintaining overall health, mobility and quality of life and will help ensure Canadians can continue to do the many activities they love.
Get Into a Daily Routine: Doing daily exercise and movement to keep your spine functioning properly may help to prevent joints from getting creaky and painful.
Educate Yourself: On World Spine Day, Canadians are encouraged to #GetSpineActive. Visit https://www.chiropractic.ca/blog/world-spine-day-2019-toolkit/ for additional information, activities and tips for staying active.
Consult a Chiropractor: Chiropractors help to keep Canadians moving. Despite a common misconception, those suffering don't need a referral to visit one. To learn more about chiropractors and how they can help, visit www.chiropractic.ca.

About World Spine Day and Back Pain Worldwide
Taking place on October 16 each year, World Spine Day has become a focus in raising awareness of back pain and other spinal issues. With health professionals, exercise and rehabilitation experts, public health advocates, schoolchildren and patients all taking part, World Spine Day will be celebrated on every continent.

World Spine Day highlights the importance of spinal health and well-being. Promotion of physical activity, good posture, responsible lifting and healthy working conditions are all encouraged, as is people looking after their spines and staying active.

With an estimated one billion people worldwide suffering from back pain, it affects all age groups, from children to the elderly. It is the biggest single cause of disability on the planet, with one in four adults estimated to suffer from back pain during their lives. Prevention is therefore key and this year's World Spine Day will be encouraging people to take steps to be kind to their spines.

About the Canadian Chiropractic Association
The Canadian Chiropractic Association (CCA) is a national association representing Canada's 9,000 licensed Doctors of Chiropractic. Approximately 4.5 million Canadians use the services of a chiropractor each year. The CCA advocates on behalf of members and their patients to advance the quality and accessibility of chiropractic care in Canada and to improve the effectiveness and efficiency of the healthcare system. For more information on the CCA or for a referral to a doctor of chiropractic, please visit www.chiropractic.ca or contact your provincial association.

SOURCE Canadian Chiropractic Association

HumanisRx launches MedMonitor, the game changer that helps reduce millions in health benefit and disability insurance costs

MARKHAM, ON, Oct. 16, 2019 /CNW/ - Canadian employees are at high risk of medication related problems, leading to serious health risks, increased absenteeism in the workplace and high disability costs for employers, according to new research.

HumanisRx today released the White Paper, A Progressive Approach to Plan Member Health: Predicting the Value of Proactively Resolving Medication Risks in Canadian Workplaces. It finds that medication related issues – such as incompatible or duplicate medications, higher than recommended doses, sub-optimal therapy or failing to take medication as prescribed – is negatively impacting employees' health, causing them to take extended leaves from their jobs. Ultimately, this leads to high benefit and disability costs for employers.

"Our research finds that employees are not optimizing their use of prescription medications – and that's a huge cost driver for Canadian employers and insurance companies," said Jeff May, President of HumanisRx. "But this trend can be reversed through our MedMonitor program and state-of-the-art software, which analyzes drug claim data and initiates pharmacist-led interventions with employees and their healthcare providers."

HumanisRx, in collaboration with Munich Re, GroupHEALTH Benefit Solutions, and Disability Management Institute, recently conducted a retrospective study which examined drug claim data. The study found:

Alerts were generated by one in every four plan members using medications, indicating at least one identified drug therapy problem that may have been related to a safety risk, sub-optimal therapy, or failing to take the drug as prescribed.
Almost 60% of the drug therapy problems identified were due to safety, meaning the plan member was at risk of an adverse outcome.

"Based on the outcomes observed in the retrospective study, we believe that there is value to insurers and plan sponsors adopting a proactive medication optimization strategy for their disability management or health and wellness programs," said Mark Foerster, Vice President Group Operations and Claims at Munich Re.

A valuation model developed by Munich Re estimates that the value of long-term disability savings from proactively identifying medication risks could potentially be up to $2.7 million for a population of 200,000 plan members if all assumptions materialize. A similar model developed by HumanisRx predicts annual short-term disability savings of $3 million for 200,000 plan members, for a total annual disability savings of $5.7 million.

Employers and insurers can reduce absence and disability costs through the implementation of HumanisRx's proactive medication optimization program called MedMonitor. Using a sophisticated set of hundreds of clinical algorithms, HumanisRx's RxCompanionä software identifies employee medication risks, triages them, and initiates an intervention with a HumanisRx pharmacist. The pharmacist then works with the employee and their healthcare providers to resolve the medication related issues and reduce health risks. Improved employee well-being results in decreased workplace absences, less need to hire replacement staff, and lower disability costs.

"Through careful monitoring and analysis of plan members' medication patterns, MedMonitor has the potential to prevent medication risks, lower presenteeism and absenteeism, and offer employers dramatic benefits and disability cost savings," said May.

About HumanisRx
HumanisRx, a division of Remedy Holdings Inc., helps Canadians with complex or unique needs get the best results from their medications. Its team of licensed pharmacists consults with plan members and their healthcare providers, offering recommendations to improve their experience with medications.

To download your copy of the White Paper, click here or contact HumanisRx.

SOURCE HumanisRx

Biomedical Zone HeathBound Start Up Challenge 2019/2020 Tackles Technology for Mental Health and Addictions

Applications to participate in this year's event open on October 21, 2019

TORONTO, Oct. 16, 2019 /CNW/ - The Biomedical Zone, a partnership between Ryerson University and St. Michael's Hospital, is pleased to announce a collaboration with Shoppers Drug Mart for its third annual Healthbound Start Up Challenge competition.

This year's challenge will focus on finding innovative, technology-driven solutions from the community that will make a tangible impact for individuals experiencing mental health and/or addiction issues. The winning teams will receive a total of $50,000 as well as residency in the Biomedical Zone health technology incubator to help grow their companies.

"We are thrilled to collaborate with Shoppers Drug Mart in offering our third annual HealthBound Start Up Challenge," said Linda Maxwell, Executive Director of the Biomedical Zone. "We look forward to working with startups from across Canada to showcase innovative and practical technology-driven solutions supporting patients' mental health. This is a timely and important challenge, providing the healthcare community, patients, and caregivers with fresh new ideas, and startups with the opportunity to collaborate with leading healthcare organizations to affect real change."

"Access to mental health resources and solutions for Canadians living with mental illness is one of the biggest challenges facing our patients, our friends and our colleagues across the country," said Theresa Firestone, Senior Vice President, Health and Wellness, Shoppers Drug Mart. "We believe innovative ideas will be required to make meaningful impact and we're excited to work with Ryerson, St. Michael's and the Biomedical Zone on this startup challenge."

HealthBound is an innovation competition that convenes health institutions, startups, clinicians, and end-users of technology to develop solutions around ubiquitous healthcare challenges.

The event's agile approach to innovation supports rapid adaptation and adoption of new technology in a healthcare setting.

Shoppers Drug Mart and the Biomedical Zone chose mental health and addictions as this year's HealthBound theme as it is one of the biggest healthcare challenges facing Canadians today. In fact, according to the Centre for Addiction and Mental Health, by the time Canadians reach 40 years of age, one in two have, or have had, a mental illness.

Previous HealthBound challenges have included addressing healthcare-associated infections, and improving the patient experience in outpatient settings.

Last year's HealthBound winner, Verto, created a technology to optimize patient flow and automate administrative tasks which has now been deployed within several Canadian hospitals.

Applications for startups to participate in HealthBound open Monday October 21, 2019 at 12:00 pm and ends on December 13, 2019. Finalists will pitch their companies to a panel of industry experts on February 13, 2019. For further information, or to apply to participate in HealthBound, visit https://www.healthbound-bmz.ca/.

About the Biomedical Zone

Founded in 2015, the Biomedical Zone is Canada's first physician-led, hospital-embedded health technology incubator. A partnership between Ryerson University and St. Michael's Hospital, the Biomedical Zone's first-in-class concurrent business and clinical validation methodology supports startup companies and demonstrates how hospitals can drive economic impact while delivering the highest quality healthcare. To date, the Biomedical Zone has hosted 37 companies and supported the creation of more than 100 startup jobs.

About Shoppers Drug Mart

Shoppers Drug Mart is one of the most recognized and trusted names in Canadian retailing. The company is the licensor of full-service retail drug stores operating under the name Shoppers Drug Mart (Pharmaprix in Québec). With almost 1,300 Shoppers Drug Mart and Pharmaprix stores operating in prime locations in each province and two territories, the company is one of the most convenient retailers in Canada. The company also licenses or owns 47 medical clinic pharmacies operating under the name Shoppers Simply Pharmacy (Pharmaprix Simplement Santé in Québec), and provides cosmetic dermatology services at two standalone locations, the Beauty Clinic. As well, the company owns and operates 43 corporate Wellwise by Shoppers Drug Mart stores and an ecommerce site Wellwise.ca, making it the largest Canadian retailer of home health care products and services. In addition to its retail store network, the company owns Shoppers Drug Mart Specialty Health Network Inc., a provider of specialty drug distribution, pharmacy and comprehensive patient support services, and MediSystem Inc., a provider of pharmaceutical products and services to long-term care facilities. Shoppers Drug Mart is an independent operating division of Loblaw Companies Limited.

SOURCE Ryerson University

30/30 Peanut Challenge Launches November 1
30 Days to Benefit from Peanut Power

Albany, Ga. (October 16, 2019) – Peanuts have it all. They’re tasty, low-cost and packed with protein, vitamins and minerals. To celebrate this superfood, The Peanut Institute is launching a 30/30 Peanut Challenge. For 30 days, Americans are encouraged to incorporate 30 peanuts or two tablespoons of peanut butter into their daily diet.

Dr. Samara Sterling, director of research for The Peanut Institute and also known as Dr. Peanut, cites peanuts’ significant health benefits as the reason for the challenge.

“Studies in the United States and around the world have found that eating peanuts regularly has been associated with a reduced risk of cancer, heart disease and diabetes. Peanut consumption has also been shown to deliver positive effects throughout the entire body and improve overall life expectancy,” explains Sterling.

Peanuts are also extremely budget friendly. Two servings of peanuts cost less than 30 cents and deliver 14 grams of power-packed plant protein.

Other benefits of consuming peanuts and peanut butter include:

Eating peanuts regularly can reduce the risk of developing cardiovascular disease by 30%.
Peanuts have 30% more protein per one-ounce serving than cashews, hazelnuts and walnuts.
A serving of peanuts contains almost 30% of daily niacin needs. Niacin can reduce the risk of developing Alzheimer’s disease by 70%.
Resveratrol, a bioactive found in peanuts, is believed to improve blood flow to the brain by as much as 30%, which helps reduce the risk of stroke.
Short-term memory, which lasts up to 30 seconds, can be improved by eating peanuts.
For the 30 million people in the U.S. who are living with Type 2 diabetes, peanuts provide a low-cost option to keep blood glucose under control.
The entire human gastrointestinal tract is about 30 feet long. Peanuts are a good source of fiber, which promotes satiety and proper digestion. Fiber also helps keep the intestines healthy.
During an average lifetime, the heart can beat more than 3 billion times. Peanuts contain arginine and other compounds, which help improve heart health and keep it beating.
Doctors recommend 30 minutes of daily exercise for everyone. Peanuts and peanut butter deliver plenty of energy to get it done, making them a favorite of fitness enthusiasts around the world.
For those who have 30 minutes (or less) for breakfast, studies show that including peanut butter can help create satiety even 8-12 hours later.

The 30/30 Peanut Challenge is easy to adopt since peanuts and peanut butter are extremely versatile and can be incorporated into breakfast, lunch, dinner and snack time. (In fact, they’re so versatile that George Washington Carver developed approximately 300 uses for peanuts, including peanut butter, flour, shaving cream, soap and skin lotion.)

For those looking to integrate peanuts into their daily meals, a peanut butter smoothie can start off the day. A peanut Cobb salad is great for lunch. A warm and hearty peanut soup or stew is ideal for a fall dinner. And, to power through the afternoon, a handful of peanuts do the trick.

“We’re encouraging everyone to join the challenge and share your experience on our social channels, #peanutchallenge,” says Sterling. “Of course, I’m going to participate so you’ll get to see how I make peanuts part of my day.”

As part of the 30/30 Peanut Challenge, The Peanut Institute is giving away 30 peanut-powered gift baskets throughout November.

For more information on peanut recipes and the peanut-powered gift basket giveaway, visit peanutinstitute.com.